A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in metastatic colorectal cancer (mCRC) patients (pts)

P Mittal;Y Yang;S Soni;F Battaglin;J Millstein;S Stintzing;A Parikh;J Lo;L Torres-Gonzalez;S Algaze;P Jayachandran;K Ashouri;A Wong;W Zhang;C Mancao;C Cremolini;V Heinemann;I Singh;H-J Lenz ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 3; abstr 182)

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer

H Arai;Y Yang;J Millstein;T Denda;F Ou;F Innocenti;H Takeda;Y Kubota;A Doi;Y Horie;K Umemoto;N Izawa;J Wang;F Battaglin;P Jayachandran;S Algaze;S Soni;W Zhang;W Zhang;R Goldberg;M Hall;A Scott;J Hwang;E Lou;B Weinberg;J Marshall;S Goel;J Xiu;M Korn;A Venook;Y Sunakawa;H-J Lenz Eur J Cancer Feb 10:201:113914. doi: 10.1016/j.ejca.2024.113914. Online ahead of print

PMid: PMID: 38359495

Acquired Genomic Alterations on First Line Chemotherapy with Cetuximab/Bevacizumab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of CALGB/SWOG-80405 Trial

K Raghav;F-S Ou;A Venook;F Innocenti;R Sun;H-J Lenz;ES Kopetz Journal of Clinical Oncology Jan 20;41(3):472-478

PMid: PMID36067452 | PMC number: PMC9870237

Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)

E Van Blarigan;C Ma;F-S Ou;T Bainter;A Venook;K Ng;D Niedzwiecki;E Giovannucci;H-J Lenz;J Shaw;B Polite;H Hochster;R Goldberg;R Mayer;CD Blanke;E O'Reilly;J Meyerhardt International Journal of Cancer Jan 15;152(2):123-136

PMid: PMID35904874 | PMC number: PMC9691576

Transcriptional Profiling and Consensus Molecular Subtype Assignment to Understand Response and Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Colorectal Cancer

S Chowdhury;R Gupta;J Millstein;K Lin;V Haridas;M Zeineddine;C Parseghian;H-J Lenz;ES Kopetz;J Shen JCO Precis Oncol. Jul;7:e2200422

PMid: PMID37487150 | PMC number: PMC10581628

Genome-wide association studies of survival in 1,520 cancer patients treated with bevacizumab-containing regimens

J Quintanilha;J Wang;A Sibley;W Xu;O Espin-Garcia;C Jiang;A Etheridge;M Ratain;H-J Lenz;M Bertagnolli;H Kindler;M Dickler;A Venook;J Liu;K Owzar;D Lin;F Innocenti International Journal of Cancer, Jan 15;150(2):279-289. doi: 10.1002/ijc.33810. Epub 2021 Oct 5

PMid: PMID34528705

Tumor immunogenomic features determine outcomes in patients with metastatic colorectal cancer of CALGB/SWOG 80405 (Alliance) treated with standard-of-care combinations of bevacizumab and cetuximab

F Innocenti;A Yazdani;N Rashid;X Qu;F-S Ou;S Van Buren;M Bertagnolli;O Kabbarah;C Blanke;A Venook;H-J Lenz;B Vincent Clinical Cancer Research Apr 14;28(8):1690-1700

PMid: PMID35176136 | PMC number: PMC9093780

ARID1A mutations induce an EGFR-like signature and confer intrinsic and acquired resistance to cetuximab treatment in colon cancer

R Johnson;X Qu;C-F Lin;L Huw;A Venkatanarayan;E Sokol;F-S Ou;N Ihuegbu;O Zill;O Kabbarah;L Wang;C Bolen;A Daemen;R Bourgon;F de Sousa e Melo;A Venook;F Innocenti;H-J Lenz;C Bais Nature Communications Sep 19;13(1):5478

PMid: PMID36117191 | PMC number: PMC9482920

Circulating tumor DNA dynamics on front line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: a biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial

K Raghav;F-S Ou;A Venook;F Innocenti;R Sun;H-J Lenz;S Kopetz ASCO Gastrointestinal Cancer Symposium (Jan 20-22, 2022, San Francisco, CA), poster session, Abst #193

Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer

H Arai;A Elliott;J Millstein;J Xiu;F-S Ou;F Innocenti;J Wang;F Battaglin;P Jayachandran;N Kawanishi;S Soni;W Zhang;D Sohal;R Goldberg;M Hall;A Scott;M Khushman;J Hwang;E Lou;B Weinberg;A Lockhart;A Shields;J Abraham;D Magee;P Stafford;J Zhang;A Venook;A Venook;W Korn;H-J Lenz Oncogene Jan;41(2):260-267

PMid: PMID34728807 | PMC number: PMC8738154

Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis

NJ McCleary;S Zhang;C Ma;F Ou;T Bainter;A Venook;D Niedzwiecki;H-J Lenz;F Innocenti;B O'Neil;H Hochster;J Atkins;R Goldberg;K Ng;R Mayer;CD Blanke;E O'Reilly;C Fuchs;J Meyerhardt Journal of Geriatric Oncology May;13(4):469-479

PMid: PMID35105521 | PMC number: PMC9058225

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC)

H Arai;Y Yang;J Millstein;Y Denda;F-S Ou;F Innocenti;H Takeda;A Doi;Y Horie;K Umemoto;N Izawa;J Wang;F Battaglin;N Kawanishi;P Jayachandran;S Soni;W Zhang;A Venook;Y Sunakawa;H-J Lenz J Clin Oncol 40, 2022 (suppl 16; abstr 3586), poster 380; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)

Gene Expression of Vitamin D (VitD) Pathway Markers and Survival in Patients (Pts) with Metastatic Colorectal Cancer (mCRC): Findings from CALGB/SWOG 80405 (Alliance)

C Kohn;F-S Ou;C Ma;N Larson;T Zemla;C Yuan;D Niedzwiecki;B Hollis;A Nixon;H-J Lenz;CD Blanke;R Goldberg;R Mayer;A Venook;E O'Reilly;J Meyerhardt;K Ng J Clin Oncol 40, 2022 (suppl 16; abstr 3553), poster 347; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)

Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405

W Zhang;F Battaglin;Y Yang;F-S Ou;F Innocenti;H Arai;S Soni;P Jayachandran;M Bertagnolli;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;CD Blanke;A Venook;O Kabbarah;J Millstein;H-J Lenz J Clin Oncol 40, 2022 (suppl 16; abstr 3580), poster 374; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)

Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance)

F Innocenti;A Sibley;S Patil;A Etheridge;C Jiang;F-S Ou;S Denning;G Casey;M Bertagnolli;H McLeod;T Auman;CD Blanke;Y Furukawa;A Venook;M Kubo;H-J Lenz;J Parker;M Ratain;K Owzar Clinical Cancer Research Jan 1;27(1):267-275

PMid: PMID32958699 | PMC number: PMC7785628

Racial Differences in Survival and Response to Therapy in Patients with Metastatic Colorectal Cancer: A Secondary Analysis of CALGB/SWOG 80405 (Alliance A151931)

R Snyder;J He;J Le-Rademacher;F-S Ou;A Dodge;T Zemla;E Paskett;G Chang;F Innocenti;CD Blanke;H-J Lenz;B Polite;A Venook Journal of Clinical Oncology, Oct 15;127(20):3801-3808

PMid: PMID34374082 | PMC number: PMC8478698

Survival of Patients with Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405

M Lipsyc-Sharf;S Zhang;F Ou;N Jackson McCleary;D Niedzwiecki;I Chang;H-J Lenz;CD Blanke;S Piawah;K Van Loon;T Bainter;A Venook;R Mayer;C Fuchs;F Innocenti;A Nixon;R Goldberg;E O'Reilly;J Meyerhardt Journal of the National Cancer Institute Oct 12;djab200. doi: 10.1093/jnci/djab200. Online ahead of print

PMid: PMID34636852

Dietary fat intake in relation to overall and progression-free survival among people with advanced or metastatic colorectal cancer: data from CALGB 80405

E Van Blarigan;C Ma;F-S Ou;A Venook;D Niedzwiecki;E Giovannucci;H-J Lenz;F Innocenti;J Shaw;B Polite;H Hochster;R Goldberg;R Mayer;CD Blanke;E O'Reilly;C Fuchs;J Meyerhardt J Clin Oncol 39, 2021 (suppl 15; abstr 3588) (American Society of Clinical Oncology Annual Meeting 2021, poster session)

Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405

K DiNardo;S Zhang;F-S Ou;C Yuan;B Guerico;V Morales-Oyarvide;E Van Blarigan;D Niedzwiecki;I-Wen Chang;H-J Lenz;CD Blanke;A Venook;R Mayer;C Fuchs;F Innocenti;A Nixon;R Goldberg;E O'Reilly;J Meyerhardt J Clin Oncol 39, 2021 (suppl 15; abstr 3568) (American Society of Clinical Oncology Annual Meeting 2021, poster session)

Plasma protein biomarkers predictive of benefit from bevacizumab versus cetuximab in colorectal cancer: Results from CALGB 80405 (Alliance)

A Nixon;A Sibley;Y Liu;A Hatch;C Jiang;F Mulkey;M Starr;J Brady;D Niedzwiecki;A Venook;H Hochster;H-J Lenz;B O'Neil;J Meyerhardt;E O'Reilly;K Owzar;F Innocenti;H Hurwitz Clinical Cancer Research Dec 29. doi: 10.1158/1078-0432.CCR-21-2389. Online ahead of print

PMid: PMID34965954

Treatment-specific gene regulatory pathways in colorectal cancer patients

A Yazdani;H-J Lenz;X Qu;M Bertagnolli;A Venook;F Innocenti American Society of Human Genetics (ASHG) Annual Meeting (October 18-22), poster, PrgmNr 2776

Clinical trials as a path toward equity [Editorial]

A Benson;R Carlos Cancer, Oct 15; 127(20):3717-3719

PMid: PMID34374076

Diabetes and Clinical Outcome in Patients with Metastatic Colorectal Cancer: CALGB 80405 (Alliance)

JC Brown;S Zhang;F-S Ou;A Venook;D Niedzwiecki;H-J Lenz;F Innocenti;BH O'Neil;JE Shaw;B Polite;H Hochster;JN Atkins;RM Goldberg;K Ng;RJ Meyer;CD Blanke;E O'Reilly;CS Fuchs;JA Meyerhardt JNCI Cancer Spectrum Oct 17; 4(1): pkz078

PMid: PMID32259016 | PMC number: PMC7043296

IGF-binding proteins, adiponectin and survival in metastatic colorectal cancer: results from CALGB (Alliance)/SWOG 80405

B Guercio;S Zhang;F-S Ou;A Venook;D Niedzwiecki;H-J Lenz;F Innocenti;M Pollak;A Nixon;B Mullen;B O'Neil;J Shaw;B Polite;A Benson;J Atkins;R Goldberg;J Brown;EM O'Reilly;R Mayer;CD Blanke;C Fuchs;J Meyerhardt JNCI Cancer Spectrum, Aug 27;5(1):pkaa074. doi: 10.1093/jncics/pkaa074. eCollection 2021 Feb.

PMid: PMID33426464 | PMC number: PMC7785047

Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer

C Mackintosh;C Yuan;F-S Ou;S Zhang;D Niedzwiecki;I-W Chang;B O'Neil;B Mullen;H-J Lenz;CD Blanke;A Venook;R Mayer;C Fuchs;F Innocenti;A Nixon;R Goldberg;E O'Reilly;J Meyerhardt;K Ng JAMA Oncology 2020 Sep 17;6(11):1713-1721. doi: 10.1001/jamaoncol.2020.3938. Online ahead of print.

PMid: PMID32940631 | PMC number: PMC7499248

Rural and urban disparities based on zip code of residence: Analyses of 834 and 2159 patients in N9741 and CALGB 80405 trials respectively.

M Malla;L Huebner;S Piawah;H-J Lenz;J Meyerhardt;E O'Reilly;CD Blanke;Q Shi;A Venook;R Goldberg J Clin Oncol 38: 2020 (suppl; abstr e16076); American Society of Clinical Oncology 2020 Annual Meeting, publication only

Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)

F Battaglin;F-S Ou;Z Qu;M Bertagnolli;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;T Zemla;CD Blanke;A Venook;C Bias;O Kabbarah;H-J Lenz;F Innocenti J Clin Oncol 38: 2020 (suppl; abstr 4086); American Society of Clinical Oncology 2020 Annual Meeting, poster

Association of diet quality with survival among people with metastatic colorectal cancer: data from CALGB/SWOG 80405 (Alliance)

E Van Blarigan;S Zhang;F-S Ou;A Venook;K Ng;C Atreya;K Van Loon;D Niedzwiecki;E Giovannucci;E Wolfe;H-J Lenz;F Innocenti;B O'Neil;J Shaw;B Polite;H Hochster;J Atkins;R Goldberg;R Mayer;CD Blanke;E O'Reilly;C Fuchs;J Meyerhardt JAMA Network Open Oct 1;3(10):e2023500

PMid: PMID33125497 | PMC number: PMC7599454

ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC

R Johnson;X Qu;J Thomas;Y Kschonsak;L Huw;F-S Ou;E Sokol;N Ihuegbu;O Zill;O Kabbarah;A Daemen;R Bourgon;A Venook;F Innocenti;H-J Lenz;F de Sousa e Melo;C Bais Cancer Research 2020;80(16 Suppl):Abstract LB-063. Proceedings of the Annual Meeting of the American Association for Cancer Research (AACR), 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA)

Plasma 25-Hydroxyvitamin D levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings From CALGB/SWOG 80405 (Alliance)

C Yuan;K Sato;B Hollis;S Zhang;D Niedzwiecki;F-S Ou;I-W Chang;BH O'Neil;F Innocenti;H-J Lenz;C Blanke;A Venook;R Mayer;C Fuchs;J Meyerhardt;K Ng Clinical Cancer Research Dec 15;25 (24):7497-7505; Sep 23 [Epub ahead of print]

PMid: PMID31548349 | PMC number: PMC6911644

On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance)

A Hatch;F-S Ou;T Zemla;M Starr;JC Brady;Y Liu;F Innocenti;J Meyerhardt;E O'Reilly;H-J Lenz;H Hurwitz;A Venook;AB Nixon J Clin Oncol 37 (suppl 4; abstr 588); ASCO GI Cancers Symposium (Jan 17-19, 2019, San Francisco, CA), poster session

Mutational analysis of metastatic colorectal cancer patients in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome

F Innocenti;F-S Ou;X Qu;P Tyler;T Zemla;Niedzwiecki;R Tam;SA Mahajan;RM Goldberg;M Bertaqnolli;CD Blanke;H Sanoff;J Atkins;B Polite;A Venook;H-J Lenz;O Kabbarah Journal of Clinical Oncology May 10;37(14):1217-1227; Mar 13:JCO1801798. doi: 10.1200/JCO.18.01798. [Epub ahead of print]

PMid: PMID30865548 | PMC number: PMC6506418

Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer

B Guercio;S Zhang;A Venook;F-S Ou;D Niedzwiecki;H-J Lenz;F Innocenti;M Mahoney;B O'Neil;JE Shaw;B Polite;H Hochster;JN Atkins;RM Goldberg;RJ Mayer;CD Blanke;CS Fuchs;JA Meyerhardt American Association for Cancer Research (March 29-Apr 3, 2019 Atlanta, Georgia), poster

Impact of Consensus Molecular Subtype (CMS) on Survival in Patients with Metastatic Colorectal Cancer: Results from SWOG/ALLIANCE 80405

H-J Lenz;F-S Ou;A Venook;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;M Bertagnolli;CD Blanke;T Zemla;X Qu;P Wirapati;S Tejpar;F Innocenti;O Kabbarah Journal of Clinical Oncology Aug 1;37(22):1876-1885; May 1[Epub ahead of print]

PMid: PMID31042420 | PMC number: PMC6675593

Diet quality and survival in metastatic colorectal cancer (CRC): data from CALGB/SWOG 80405 (Alliance)

E Van Blarigan;S Zhang;F-S Ou;A Venook;K Ng;C Atreya;D Niedzwiecki;E Giovannucci;H-J Lenz;F Innocenti;BH O'Neil;JE Shaw;B Polite;H Hochster;J Atkins;R Goldberg;RJ Mayer;CD Blanke;E O'Reilly;C Fuchs;J Meyerhardt American Institute for Cancer Research (AICR) Conference (May 15-17, 2019, Chapel Hill, NC), accepted, poster

Associations of Insulin-Like Growth Factor Binding Proteins and Adiponectin with Disease Progression and Mortality in Metastatic Colorectal Cancer: Results from CALGB/SWOG 80405 (Alliance)

B Guercio;A Venook;S Zhang;F-S Ou;D Niedzwiecki;H-J Lenz;F Innocenti;M Pollak;AB Nixon;M Mahoney;B O'Neil;J Shaw;B Polite;CS Denlinger;J Atkins;R Goldberg;R Mayer;CD Blanke;CS Fuchs;J Meyerhardt J Clin Oncol 37(suppl; abstr 3035); American Society of Clinical Oncology (5/31- 6/4/2019, Chicago IL), poster session

Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB(Alliance)/SWOG 80405

B Guercio;S Zhang;F-S Ou;A Venook;D Niedzwiecki;H-J Lenz;F Innocenti;B O'Neil;JE Shaw;B Polite;H Hochster;J Atkins;R Goldberg;K Sato;K Ng;E Van Blarigan;RJ Mayer;CD Blanke;E O'Reilly;C Fuchs;J Meyerhardt Journal of Clinical Oncology Oct 10;37(29):2620-2631

PMid: PMID31408415 | PMC number: PMC6900834

Next-generation sequencing (NGS) in patients (pts) with metastatic colorectal cancer (mCRC): novel mutated genes and differential response to therapy (Alliance)

F Innocenti;N Rashid;M Wancen;F-S Ou;X Qu;S Denning;M Bertagnolli;CD Blanke;A Venook;O Kabbarah;H-J Lenz Annals of Oncology 30 (suppl_5): v198-v252; European Society for Medical Oncology (ESMO), (Sept 27-Oct 1, 2019, Barcelona, Spain),

Association of RAS mutations with race in metastatic colorectal cancer:CALGB/SWOG 80405 (ALLIANCE)

A Sehdev;D Niedzwiecki;A Venook;H-J Lenz;F Innocenti;MR Mahoney;JE Shaw;BN Polite;HS Hochster;JN Atkins;RM Goldberg;RJ Mayer;RL Schilsky;M Bertagnoilli;CD Blanke;B O'Neill Journal of Clinical Oncology 36(suppl 4S; abstr 638); ASCO Gastrointestinal Cancers Symposium 2018 (January 18-20, 2018, San Francisco, CA), poster session

Causal modeling of CALGB 80405 identifies network drivers of metastatic colorectal cancer (CRC)

F Innocenti;H-J Lenz;J Meyerhardt;D Niedzwiecki;A Nixon;E O'Reilly;F-S Ou;A Venook;RK Das;L Furchtgott;D Cunha;K Rich;J Latourelle;D Wuest;B Hayete;I Khalil J Clin Oncol 36, 2018 (suppl; abstr 3570); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), poster session

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension

M Li;F Mulkey;C Jiang;B O'Neil;B Schneider;F Shen;P Friedman;Y Momozawa;M Kubo;D Niedzwiecki;H Hochster;H-J Lenz;JN Atkins;H Rugo;S Halabi;W Kelly;H McLeod;F Innocenti;M Retain;A Venook;K Owzar;D Kroetz Clinical Cancer Research Oct 1;24(19):4734-4744

PMid: PMID29871907 | PMC number: PMC6168379

Associations of physical activity with survival and progression in metastatic colorectal cancer: results from CALGB 80405 (Alliance)

B Guercio;A Venook;D Niedzwiecki;S Zhang;K Sato;C Fuchs;H-J Lenz;F Innocenti;B Fruth;E Van Blarigan;B O'Neil;JE Shaw;B Polite;H Hochster;J Atkins;R Goldberg;R Mayer;M Bertagnolli;C Blanke;J Meyerhardt Journal of Clinical Oncology 35, 2017 (suppl 4S; abstract 659); ASCO GI Cancers Symposium (Jan 19-21, 2017, San Francisco, CA), poster, abst.#659

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial

A Venook;D Niedzwiecki;H-J Lenz;F Innocenti;B Fruth;JA Meyerhardt;D Schrag;C Greene;BH O'Neil;JE Shaw;JN Atkins;AB El-Khoueiry;S Berry;B Polite;EM O'Reilly;R Goldberg;H Hochster;R Schilsky;M Bertagnolli;RJ Mayer;CD Blanke Journal of the American Medical Association Jun 20;317(23):2392-2401

PMid: PMID28632865 | PMC number: PMC5545896

Primary tumor location is an independent prognostic maker from CMS and MSI for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

A Venook;FS Ou;F Innocenti;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;M Bertagnolli;C Blanke;T Zemla;X Qu;O Kabbarah;H Lenz J Clin Oncol 35, 2017 (suppl; abstr 3503); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral

Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 Alliance)

F Innocenti;FS Qu;T Zemla;D Niedzwiecki;X Qu;R Tam;SA Mahajan;R Goldberg;RJ Mayer;M Bertagnolli;H Hochster;C Blanke;A Venook;H Lenz;O Kabbarah J Clin Oncol 35, 2017 (suppl; abstr 3504); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral

Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

H Lenz;FS Ou;A Venook;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;M Bertagnolli;C Blanke;T Zemla;X Qu;O Kabbarah;F Innocenti J Clin Oncol 35, 2017 (suppl; abstr 3511); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presentation

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

D Arnold;B Lueza;JY Douillard;M Peeters;H-J Lenz;A Venook;V Heinemann;E Van Cutsem;J Pignon;J Tabernero;A Cervantes;F Ciadiello Annals of Oncology Aug 1;28(8):1713-1729

PMid: PMID28407110 | PMC number: PMC6246616

Variants associated with high grade bevacizumab-induced hypertension identified by exome sequencing: CALGB 80405 (Alliance).

M Li;F Mulkey;C Jiang;B O'Neil;D Niedzwiecki;P Friedman;H Hochster;H Lenz;A Venook;K Owzar;D Kroetz American Society for Clinical Pharmacology and Therapeutics (March 8-12, San Diego, CA), late breaking poster session abst. #LB-041, p. 164

Impact of primary (1º) tumor location on overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405

A Venook;D Niedzwiecki;F Innocenti;M Fruth;C Greene;B O'Neil;JE Shaw;B Polite;H Hochster;C Blanke;R Goldberg;R Schilsky;R Mayer;M Bertagnolli;H Lenz Journal of Clinical Oncology 34, 2016 (suppl; abstr 3504); oral American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL),

Blood-Based Biomarkers in Patients (pts) with Metastatic Colorectal Cancer (mCRC) Treated with FOLFOX or FOLFIRI + Bevacizumab (Bev), Cetuximab (Cetux), or Bev + Cetux: Results from CALGB 80405 (Alliance)

AB Nixon;AB Sibley;AJ Hatch;Y Liu;C Jiang;F Mulkey;MD Starr;JC Brady;D Niedzwiecki;F Innocenti;A Venook;H Hochster;H Lenz;B O'Neil;K Owzar;H Hurwitz Journal of Clinical Oncology 34, 2016 (suppl; abstr 3597); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session

Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: economic analysis of CALGB/SWOG 80405

D Schrag;A Dueck;M Naughton;D Niedzwiecki;C Earle;J Shaw;A Grothey;H Hochster;C Blanke;A Venook Journal of Clinical Oncology 33:5s (suppl; abstr 6504); American Society of Clinical Oncology Annual Meeting (May 29-June 2,2015, Chicago, IL), oral;

Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance)

K Ng;AP Venook;K Sato;BW Hollis;D Niedzwiecki;C Ye;I-W Chang;BH O'Neil;F Innocenti;H-J Lenz;CD Blanke;CS Fuchs;JA Meyerhardt Journal of Clinical Oncology 33(suppl 3; abstr 507); poster; ASCO Gastrointestinal Cancers Sympos (Jan 15-17, 2015, San Francisco, CA);

Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405

V Heinemann;D Niedzwiecki;R Pearline;H Lenz;F Innocenti;H Hochster;A Grothey;RM Goldberg;RJ Mayer;RL Schilsky;M Bertagnolli;C Blanke;A Venook;S Stinzing;BH O'Neil Journal of Clinical Oncology 33:5s (suppl; abstr 3585); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session;

Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance)

K Ng;A Venook;K Sato;K Holllis;D Niedzwiecki;C Ye;I Chang;BH O'Neil;F Innocenti;H Lenz;C Blanke;RJ Mayer;C Fuchs;JA Meyerhardt Journal of Clinical Oncology 33:5s (suppl; abstr 3503); American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation;

A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

F Innocenti;K Owzar;C Jiang;A Sibley;D Niedzwiecki;M Bertagnolli;PN Friedman;Y Furukawa;M Kubo;M Ratain;CD Blanke;H-J Lenz;A Venook;H McLeod Journal of Clinical Oncology 33:5s (suppl; abstr 3599); American Society of Clinical Oncology Annual Meeting, poster session;

A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

F Innocenti;K Owzar;C Jiang;AB Sibley;D Niedzwiecki;M Bertagnolli;P Friedman;Y Furukawa;M Kubo;M Ratain;CD Blanke;H Lenz;A Venook;H McLeod European Cancer Congress (ESMO) Annual Meeting, (Sept 25-29 2015, Vienna, Austria) oral presentation, abst. 2007;

CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (uMCRC).

AP Venook;D Niedzwiecki;H-J Lenz;F Innocenti;MR Mahoney;BH O'Neil;JE Shaw;BN Polite;H Hochster;JN Atkins;RM Goldberg;RJ Mayer;RL Schilsky;M Bertagnolli;CD Blanke Journal of Clinical Oncology 32:5s (suppl; abstr LBA3); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), scientific plenary session (oral);

CALGB/SWOG C80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC)

H Lenz;D Niedzwiecki;F Innocenti;C Blanke;MR Mahoney;BH O'Neil;JE Shaw;B Polite;H Hochster;J Atkins;RM Goldberg;RJ Mayer;RL Schilsky;M Bertagnolli;A Venook Annals of Oncology 25 (Suppl 4): iv1 - mdu438.66; ESMO 2014 Congress (Sept 26-30, 2014, Madrid, Spain), oral presentation;

Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405

K Van Loon;D Wigler;D Niedzwiecki;AP Venook;C Fuchs;C Blanke;L Saltz;RM Goldberg;JA Meyerhardt Clinical Colorectal Cancer 12(2):95-102;

PMid: PMID23317558 | PMC number: PMC3790266

Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 trial: a phase II trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarinoma

AP Venook;CD Blanke;D Niedzwiecki;HJ Lenz;JR Taylor;DR Hollis;S Sutherland;RM Goldberg Clinical Colorectal Cancer 6(7):536-538

PMid: PMID17553204

Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma PMID16356309

A Venook;C Blanke;D Niedzwiecki;HJ Lenz;J Taylor;D Hollis;S Sutherland;R Goldberg Clinical Colorectal Cancer 5(4):292-294